

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet	1	of	2
-------	---	----	---

**C mplete if Known**

Application Number	09/600,125
Filing Date	April 10, 2002
First Named Inventor	R.C. Warrington
Group Art Unit	1614
Examiner Name	Frederick Krass
Attorney Docket Number	10242-32

[illegible][illegible]Date  
Considered

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

**Complete if Known**

Application Number	09/600,125
Filing Date	April 10, 2002
First Named Inventor	R.C. Warrington
Group Art Unit	1614
Examiner Name	Frederick Krass
Attorney Docket Number	10242-32

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
FK	1.	WARRINGTON, R.C. et al., "Modulation of anticancer drug toxicity by L-histidinol: A route for improving human cancer chemotherapy?", Drugs of the Future, 1993, pp. 743-749	
FK	2.	WARRINGTON, R.C. et al., "L-Histidinol in experimental chemotherapy: improving the selectivity and efficacy of anticancer drugs, eliminating metastatic disease and revering the multi-drug resistant phenotype", Biochemistry & Cell Biology, 1992, pp. 365-375, Vol. 70.	
FK	3.	WARRINGTON, R.C. et al., "Histidinol-Mediated Enhancement of the Specificity of Two Anticancer Drugs in Mice Bearing Leukemic Bone Marrow Disease", Journal of the National Cancer Institute, 1985, pp. 1070-77, Vol. 71.	

Examiner  
Signature

Krass

Date  
Considered

02/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.